• Exact Sciences (EXAS) reported Q3 2025 revenue of $850.74 million, a 20% year-over-year increase, significantly beating earnings expectations.
  • The company raised its full-year revenue guidance to between $3.22 billion and $3.235 billion and is projected to achieve positive EPS for 2025.
  • Strong performance was driven by record cash flow and the successful launch of its multi-cancer early detection test, Cancerguard, sending shares up over 7%.

Exact Sciences Corporation delivered a powerful third-quarter performance that has reignited investor confidence, with shares climbing more than 7% in after-hours trading following the announcement. The cancer diagnostics leader posted earnings per share of $0.28, handily surpassing the $0.16 consensus estimate, on the back of record quarterly revenue.

The results have prompted a swift reassessment on Wall Street. "The beat was across the board, but the sustainability of their cash flow generation is what stands out," said an analyst who asked not to be named because their firm's official upgrade is still pending. BTIG raised its price target on the stock to $85, while CFRA lifted its target to $75, a significant jump from a previous $45.

Central to the bullish sentiment is the company's progress toward sustained profitability. Management now expects to finish the year with a positive EPS of $0.48, a milestone that has long been anticipated by the market. The quarter also saw record free cash flow and operating cash flow, providing the company with greater financial flexibility to fund its growth initiatives without relying on external capital.

A key growth lever has been the rollout of Cancerguard, the company's multi-cancer early detection test. Efforts to expand its commercial footprint received a major boost from a recently solidified partnership with Quest Diagnostics, which will make the test available through more than 7,000 patient service centers. "We are focused on delivering innovative tests that meet critical patient needs, and our strong execution this quarter reflects that commitment," CEO Kevin Conroy said in a statement accompanying the earnings release.

The company's flagship product, Cologuard, continues to be a steady revenue driver, with studies showing it increases screening compliance, particularly in underserved communities. This societal impact, coupled with a stable regulatory environment and expanding reimbursement for preventive screenings, underpins the positive long-term thesis for Exact Sciences.

With the stock now up 17.8% year-to-date, dramatically outperforming the broader medical sector, the question is whether the current momentum can be sustained. For now, the combination of blown-out earnings, raised guidance, and a clear path to profitability has given investors plenty of reasons to be optimistic.

Correction: An earlier version of this article misstated the previous analyst price target from CFRA. It was $45, not $40.